(6R,7R)-7-((Z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-3-((4-(1-methylpyridin-1-ium-4-yl)thiazol-2-yl)thio)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | 229016-73-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (6R,7R)-7-((Z)-2-(ethoxyimino)-2-(5-(phosphonoamino)-1,2,4-thiadiazol-3-yl)acetamido)-3-((4-(1-methylpyridin-1-ium-4-yl)thiazol-2-yl)thio)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
• 英文别名: (6R,7R)-7-[[(2E)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
• CAS: 229016-73-3
• 化学式: C22H21N8O8PS4
• 分子量: 684.7
• InChiKey: ZCCUWMICIWSJIX-XHNDKCDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  43
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  330
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• CEPHALOSPORIN COMPOSITIONS AND METHODS OF MANUFACTURE
  申请人：Cubist Pharmaceuticals, Inc.

  公开号：US20150111853A1

  公开（公告）日：2015-04-23

  Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising the conversion of a protected 7-amino group into a 7-carboxamide moiety in a single step.

  本文提供了一种头孢菌素抗生素化合物合成的方法，包括将保护的7-氨基团一步转化为7-羧酰胺基团。
• Compositions and methods of treatment comprising ceftaroline
  申请人：Astrazeneca AB

  公开号：EP2889034A2

  公开（公告）日：2015-07-01

  The present invention provides compositions comprising ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infection, which include administering an effective amount of ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent.

  本发明提供了包含头孢他啶或其药学上可接受的盐、溶液剂或原药单独或与抗菌剂组合的组合物。本发明提供了治疗细菌感染的方法，其中包括施用有效量的头孢他啶或其药学上可接受的盐、溶液剂或原药，单独施用或与抗菌剂联合施用。
• POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104
  申请人：PFIZER IRELAND PHARMACEUTICALS

  公开号：EP3269717A1

  公开（公告）日：2018-01-17

  The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide of formula (I) in crystallised polymorphic form "B". The compound of the invention can be used as a medicament, in particular as a beta-lactamase inhibitor.

  本发明涉及式 (I) 的 (1R,2S,5R)-7-氧代-6-磺氧基-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺钠盐 的结晶多晶型 "B"。本发明的化合物可用作药物，尤其是β-内酰胺酶抑制剂。
• POLYMORPHIC FORM OF AVIBACTAM SODIUM (NXL104)
  申请人：PFIZER IRELAND PHARMACEUTICALS

  公开号：EP3505518A1

  公开（公告）日：2019-07-03

  The invention relates to the sodium salt of (1R,2S,5R)-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamide of formula (I) in crystallised polymorphic form "D". The compound of the invention can be used as a medicament, in particular as a beta-lactamase inhibitor.

  本发明涉及式 (I) 的 (1R,2S,5R)-7-氧代-6-磺氧基-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺钠盐 的结晶多晶型 "D"。本发明的化合物可用作药物，尤其是β-内酰胺酶抑制剂。
• POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF A PHARMACEUTICAL COMPOUND
  申请人：Pfizer Ireland Pharmaceuticals

  公开号：EP2486038B1

  公开（公告）日：2017-08-30